Introduction
Macrophage infiltration is frequently observed in solid tumors. 1 Recent studies indicate that tumor-associated macrophages (TAMs) are significantly involved in tumor progression, accelerating the local invasion and metastatic dissemination of malignant cells. 2 Other studies have highlighted the possibility that macrophages may also mediate a tumoricidal effect, leading to the development of macrophage-based anticancer therapies. As a standalone example, the transfer of autologous monocyte-derived macrophages activated with interferon (IFN) γ ex vivo has been tested as a potential intervention for patients with solid tumors. 3 However, no clear therapeutic benefit has thus far associated with macrophage-based anticancer therapies. To optimize the efficacy of such an approach, improvements of the method for supplying macrophages are necessary. Indeed, if sufficient amounts of macrophages exerting potent anticancer effects could be repeatedly administered, patients may achieve robust clinical benefit from this cell-based immunotherapeutic regimen.
iPSC-Derived Proliferating Myeloid Cells
Several groups, including ours, have thus far established methods to generate macrophages from mouse or human inducible pluripotent stem cells (iPSCs). 4, 5 However, the number of macrophages generated from human iPSCs is only 10-20 times higher than the number of undifferentiated iPSCs used as starting material. In addition, the generation of macrophages from iPSCs is timeconsuming, laborious, and too expensive to be applied to the clinical practice.
Recently, we established a method to induce proliferation of the iPSCderived myeloid cells (iPS-MCs) by the lentivirus-mediated transduction of genes that promote cell proliferation or inhibit cell senescence, i.e., v-myc avian myelocytomatosis viral oncogene homolog (MYC) plus BMI1, to generate an iPSC-derived myeloid/macrophage cell line (iPS-ML). Such an iPS-ML can proliferate in a colony stimulating factor 1 (CSF1)-dependent manner for at least several months while retaining the potential to differentiate into dendritic cells (iPS-ML-DCs) with a potent T cellstimulating capacity. 
Accumulation and Infiltration of Intraperitoneally Injected iPS-ML in Tumor Tissues
We examined whether or not iPS-ML administered intraperitoneally would infiltrate tumor lesions pre-established in the peritoneal cavity of mice. 7 To this end, green fluorescent protein (GFP)-expressing NUGC-4 human gastric cancer cells, which have been established from a peritoneal metastatic lesion removed from an individual with diffuse gastric cancer, were intraperitoneally injected into SCID mice. After 15 d, iPS-ML labeled with the red fluorescent dye PKH26 were administered via the same route. Macroscopic fluorescence analysis on the next day revealed that both NUGC-4-derived tumors and iPS-ML localize for the most part to the greater omentum, demonstrating that iPS-ML efficiently accumulate into neoplastic lesions. Of note, such a preferential accumulation of iPS-ML into the greater omentum was not observed when we established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPsCs). when injected intraperitoneally into mice carrying established peritoneal tumors, iPsC-derived myeloid cells (iPs-MCs) efficiently accumulated within neoplastic lesions. The intraperitoneal injection of iPs-MCs expressing interferon β significantly inhibited the growth of human gastric and pancreatic cancers implanted in the peritoneal cavity of immunocompromised mice.
iPS-ML were inoculated into tumorfree mice. Next, we isolated and microscopically examined neoplastic lesions. PKH26-labeled iPS-ML infiltrated nests of GFP-expressing NUGC-4 cells. Higher magnification analysis of tumor sections clearly demonstrated the infiltration of iPS-ML into the neoplastic tissue. These results indicate that iPS-ML efficiently infiltrate malignant tissues when intraperitoneally injected into mice carrying cancers established in the peritoneal cavity.
Therapeutic Effects of IFNβ-Secreting iPS-ML on Peritoneally Disseminated NUGC-4 Gastric Cancer Cells in Xenograft Models
IFNβ exerts anti-proliferative and/or pro-apoptotic effects on various types of cancer cells. We examined the effects of iPS-ML genetically modified to secrete IFNβ (iPS-ML/IFNβ) against NUGC-4 cells in vivo. 7 We generated NUGC-4 cells expressing the firefly luciferase, NUGC4/ Luc cells, which can be easily monitored in vivo by bioluminescence analysis. SCID mice were then inoculated with NUGC-4/ Luc cells (day 0), and 4 d later they were divided into a treated and a control group. Mice belonging to the treated group were injected i.p. with iPS-ML/IFNβ from day 4 (2 × 10 7 cells/injection/mouse, 3 injections per week). Tumor growth was significantly inhibited by the inoculation of iPS-ML/IFNβ cells. Of note, the administration of iPS-ML/IFNβ also inhibited the growth of MIAPaCa-2 pancreatic cancer cells in a similar xenograft model. In summary, iPS-MCs expressing IFNβ potently inhibit the growth of human gastric and pancreatic cancers growing in immunocompromised SCID mice.
Toward Clinical Applications
Gastric cancer is one of most frequent malignancies worldwide and the second most frequent cause of cancer-related mortality. Peritoneal dissemination is the most difficult type of metastasis to treat of those associated with gastric cancer. Pancreatic cancer has a poor prognosis, with overall 5-y survival rate being < 10%. Thus, efficient therapies for these intractable cancers are urgently needed. The present study suggests that iPS-MCs secreting antineoplastic factors may be used to treat cancers for which no standard therapy has been established yet.
For macrophage-based immunotherapeutic regimens to achieve robust clinical effects, cancer patients may need to receive repetitive administrations of large numbers of cells. Since our iPS-ML proliferates for at least several months, sufficient amounts of iPS-MCs may be readily available by this approach. However, the proliferative capacity of our iPS-ML may constitute a concern, as this line could drive leukemogenesis, at least theoretically, in a completely autologous setting.
To circumvent such risk, we plan to use allogeneic iPS-ML lacking transporter associated with antigen presentation (TAP) for future clinical applications. TAP plays a key role in antigen-presentation by MHC class I molecules. In TAPdeficient cells, the expression levels of MHC class I molecules on the cell surface are very low. More importantly, the lack of TAP greatly reduces the complexity of peptides presented on MHC class I molecules. In line with these notions, we previously demonstrated that TAP-deficient cells evade recognition by most alloreactive CD8 + T cells (the major immune effector cells mediating acute rejection) upon transfer into allogeneic recipients. 8 Nevertheless, alloreactive CD8 + T cells recognizing MHC class I-bound peptides presented via the TAP-independent pathway (mainly derived from signal peptides) may eventually eliminate the allogeneic TAP-deficient iPS-MCs. Based on these premises, we predict that TAP-deficient iPS-MCs would survive in the recipient for several days, allowing them to exert anticancer effects, but would then be eliminated by the recipient's immune system. Thus, the administration of allogeneic, TAP-deficient iPS-MCs to cancer patients should be effective and safe. (Fig. 1) 
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